Lam Research Corporation
230.10USD
-0.0500 (-0.02%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LRCX.
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 17.4B | 14.9B | 18.4B | 23.2B | 35.4B | 42.7B |
| Q1 | 5.1B | 3.5B | 4.2B | 5.3B | 8.2B | — |
| Q2 | 5.3B | 3.8B | 4.4B | 5.3B | 8.6B | — |
| Q3 | 3.9B | 3.8B | 4.7B | 5.8B | 9.0B | — |
| Q4 | 3.2B* | 3.9B* | 5.2B* | 6.7B* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 3.32 | 2.90 | 4.15 | 5.76 | 9.63 | 12.15 |
| Q1 | 1.04 | .670 | .860 | 1.24 | 2.19 | — |
| Q2 | 1.08 | .720 | .920 | 1.26 | 2.35 | — |
| Q3 | .601 | .730 | 1.03 | 1.45 | 2.48 | — |
| Q4 | .591* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| .773* |
| 1.33* |
| 1.81* |
| — |
| — |
Debt level and coverage